SGLT2 inhibitor ertugliflozin decreases elevated intracellular sodium, and improves energetics and contractile function in diabetic cardiomyopathy-Reference-Cited by-同舟云学术

SGLT2 inhibitor ertugliflozin decreases elevated intracellular sodium, and improves energetics and contractile function in diabetic cardiomyopathy

Published:2023-04 Issue: Volume:160 Page:114310
ISSN:0753-3322
Container-title:Biomedicine & Pharmacotherapy
language:en
Short-container-title:Biomedicine & Pharmacotherapy

Author:

Croteau Dominique,Baka Tomas,Young Sara,He Huamei,Chambers Jordan M.,Qin Fuzhong,Panagia Marcello,Pimentel David R.,Balschi James A.,Colucci Wilson S.,Luptak Ivan^ORCID

Funder

American Heart Association

Merck

National Institutes of Health

Publisher

Elsevier BV

Subject

Pharmacology,General Medicine

Reference21 articles.

1. Basic mechanisms of diabetic heart disease;Ritchie;Circ. Res.,2020

2. Current status on the therapeutic strategies for heart failure and diabetic cardiomyopathy;Kim;Biomed. Pharmacother.,2022

3. Effects of SGLT2 inhibitors on cardiovascular, renal, and major safety outcomes in heart failure: a meta-analysis of randomized controlled trials;Li;Int. J. Cardiol.,2021

4. Effects of SGLT2 inhibitors on ion homeostasis and oxidative stress associated mechanisms in heart failure;Gager;Biomed. Pharmacother.,2021

5. Empagliflozin reduces oxidative stress through inhibition of the novel inflammation/NHE/[Na+]c/ROS-pathway in human endothelial cells;Uthman;Biomed. Pharmacother.,2022

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multi-omics reveals bufadienolide Q-markers of Bufonis Venenum based on antitumor activity and cardiovascular toxicity in zebrafish;Phytomedicine;2024-10

2. SGLT2 inhibitors: how do they affect the cardiac cells;Molecular and Cellular Biochemistry;2024-08-19

3. Examining the Impact of Ertugliflozin on Cardiovascular Outcomes in Patients with Diabetes and Metabolic Syndrome: A Systematic Review of Clinical Trials;Pharmaceuticals;2024-07-11

4. Cardiovascular outcomes and molecular targets for the cardiac effects of Sodium-Glucose Cotransporter 2 Inhibitors: A systematic review;Biomedicine & Pharmacotherapy;2024-06

5. Underlying mechanisms and cardioprotective effects of SGLT2i and GLP-1Ra: insights from cardiovascular magnetic resonance;Cardiovascular Diabetology;2024-03-11